2020 UAB Cardiovascular Institute Annual Report CVI Annual Report 2019-2020 6 | Page 10

UAB’s Structural Heart and Valve Program has expertise in all aspects of valve-related surgery, including
procedures treating infectious disease, stenotic and insufficient valves, and congenital valvular heart disease.
Both standard open and minimally invasive valve repair/replacement (transcatheter and robotic approaches)
procedures are performed. In addition to transcatheter aortic valve replacement (TAVR), we offer aortic and mitral
valve treatment, valvuloplasty, valve replacement surgery, valve-sparing aortic root replacement, and the Ross
procedure. Transcatheter mitral valve and tricuspid valve repair techniques also are available.
UAB performed more than 4,200 valve procedures from 2014 to 2019 and received a high-performing rank for
aortic valve surgery care in 2019 from USNWR.
STS COMPOSITE QUALITY RATINGS
2019 UAB STS OVERALL COMPOSITE
QUALITY RATINGS
Isolated AVR
HH
CABG + AVR
HHH
MVRR
HHH
CABG + MVRR
HHH
UAB PARTICIPANT
SCORE STS COMPOSITE
QUALITY RATING
96.2% Not statistically
different than
the STS mean
95.4% Significantly higher
than the STS mean
93.6% Significantly higher
than the STS mean
92.8% Significantly higher
than the STS mean
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
UAB’s transcatheter aortic valve replacement (TAVR) program began in August 2012 as the first of its kind in
Alabama and features a multidisciplinary team of 4 cardiovascular surgeons, 5 interventional cardiologists,
advanced practitioners, nurses, psychologists, and members of a quality team, all of whom collaborate to provide
comprehensive, quality, and patient-centered care. The UAB valve team also performs valve-in-valve procedures in
the mitral, pulmonic, and tricuspid valve positions. This innovative technology offers options for patients deemed
too high risk for an open valve procedure and allows for shorter recovery and a faster return to a better quality of
life. Transcatheter valves are implanted using various approaches, such as transfemoral/transcaval, transaortic,
transapical, transcarotid, suprasternal, and transaxillary/subclavian.
Source: STS Harvest Period #3 - Period ended 6/30/2019 Recent growth in UAB’s Structural Heart and Valve Program will position UAB to be one of the largest TAVR programs
in the nation.
UAB received an overall composite quality rating of 3 stars in three of the four STS Valve Categories. A 3-star
rating denotes that performance is significantly higher than the STS mean, based on 97.5% Bayesian probability.
A 2-star rating denotes that UAB’s performance is not statistically different from the STS mean. PROGRAM HIGHLIGHTS
OPEN SURGICAL VALVE PROCEDURES BREAKDOWN 2014–2019 (N=4,238)
The UAB Structural Heart
and Valve Program offers
interventional and surgical
treatment options including:
• Aortic valve replacement/
repair
• Tricuspid valve
replacement/repair
• Pulmonary valve
replacement/repair
• Mitral valve replacement/
repair
• Valve-sparing aortic root
replacement
• Paravalvular leak repair
8
SURGICAL ISOLATED MV REPAIR VS.
TRANSCATHETER MV REPAIR (MITRACLIP) 2014–2019
STRUCTURAL HEART & VALVE DISEASE
SURGICAL ISOLATED MVR VS.
TRANSCATHETER MVR 2014–2019
UAB Cardiovascular Institute Annual Report
Pulmonary Valve
Procedures
N=80 (1.9%)
Aortic Valve
Procedures
N=3028 (71.4%)
Mitral Valve
Procedures
N=1293 (30.5%)
Tricuspid Valve
Procedures
N=301 (7.1%)
• State-of-the-art endovascular/hybrid operating room with a dedicated focus on treating patients with valve disease
• Performed more than 1,300 TAVR procedures since program inception in 2012
• Alabama’s most experienced leader in transcatheter valve-in-valve replacement procedures
• Identification of potential new transcatheter valves and delivery systems to improve patient safety and effectiveness
for those undergoing TAVR
• Pediatric cardiologists collaborate closely with structural heart team in treating congenital heart disease.
• One of the few medical centers that offers minimally invasive ascending aortic repair/replacement
• Performed 250 MitraClip procedures since 2014
• UAB was one of the first on the East Coast to use ABBOTT’s G4 MitraClip device.
• UAB was involved in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy (COAPT) for
Heart Failure Patients with Functional Mitral Regurgitation clinical trial.
HIGHLIGHTS
• Additional research efforts focus on identifying potential new patient populations that could benefit from the less
invasive valve procedures.
• UAB’s structural heart and valve team participates in industry-leading clinical trials involving the aortic valve,
such as:
– EARLY TAVR - Evaluation of Transcatheter Aortic Valve Replacement compared to SurveilLance for patients
with Asymptomatic Severe Aortic Stenosis
– Reprise IV - Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of
LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
uabmedicine.org
9